For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.